References

nodgo

Российский журнал детской гематологии и онкологии (РЖДГиО)

Russian Journal of Pediatric Hematology and Oncology

2311-12672413-5496

LTD “Graphica”

10.21682/2311-1267-2019-6-1-48-55

nodgo-471

Research Article

ОБЗОРЫ ЛИТЕРАТУРЫ

LITERATURE REVIEWS

Продолжение адъювантной химиотерапии при остеогенной саркоме, резистентной к неоадъювантному лечению. Осмысленные действия или привычка?

Continuation of adjuvant chemotherapy for osteosarcoma resistant to neoadjuvant treatment. Meaningful action or habit?

https://orcid.org/0000-0002-9054-5068

Жуков

Н. В.

Zhukov

N. V.

д.м.н., профессор, руководитель отдела мультидисциплинарной онкологии

Researcher ID: I-3833-2018

SPIN-код: 8151-9305

Dr. of Sci. (Med.), Professor, Head of Multidisciplinary Oncology Department Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

Researcher ID: I-3833-2018

SPIN-code: 8151-9305

zhukov.nikolay@rambler.ru

ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России; ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian Federation

2019

11022019

614855

2019

Жуков Н.В.

Zhukov N.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nodgo.org/jour/article/view/471

Химиотерапия (ХТ) значимо увеличила шанс на излечение больных с резектабельной остеогенной саркомой и сейчас является неотъемлемой частью их лечения. При этом стандартный подход, предусматривающий введение всем пациентам одних и тех же цитостатиков (доксорубицин, цисплатин, метотрексат) и перед, и после операции, остается неизменным на протяжении последних десятилетий. К сожалению, результаты его использования у больных с плохим ответом (патоморфозом) опухоли на предоперационную ХТ малоудовлетворительны, а недавно завершившиеся исследования не показали их улучшения за счет интенсификации послеоперационной ХТ. В результате стандартом лечения этих больных остается продолжение после операции ХТ, оказавшейся неэффективной на дооперационном этапе. Статья посвящена критическому анализу целесообразности подобной практики и оценке возможных позитивных и негативных последствий отказа от послеоперационной ХТ у больных с плохим патоморфозом опухоли.

Chemotherapy (CT) has significantly increased the chance of cure for patients with resectable osteogenic sarcoma and is now an integral part of their treatment. At the same time, the standard approach is represented by administration of the same СT (doxorubicin, cisplatin, methotrexate) to all patients both before and after the surgery has remained unchanged over the past decades. Unfortunately, the results of its application in patients with a poor pathologic response of a tumor to preoperative CT are not satisfactory, and recently published studies have not shown their improvement due to the intensification of postoperative CT. As a result, the standard of treatment for these patients remains a continuation after surgery the same CT, which has proved ineffective at the preoperative stage. The article is devoted to a critical analysis of the feasibility of such practices and an assessment of the possible positive and negative consequences of the rejection of postoperative CT in patients with poor pathologic response.

остеогенная саркомалечебный патоморфознеоадъювантная терапияадъювантная терапиявыживаемостьклинические исследования

osteogenic sarcomamedical pathomorphosisneoadjuvant therapyadjuvant therapysurvivalclinical studies

Исследование проведено без спонсорской поддержки.

The study was performed without external funding.

References1

DeVita V.T. Jr., Lawrence T.S., Rosenberg S.A. DeVita, Hellman, and Rosenbergs Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Friedman M.A., Carter S.K. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 1972;4(5): 482–510. PMID: 4566220.

Sutow W.W., Sullivan M.P., Fernbach D.J., Cangir A., George S.L. Adjuvant chemotherapy in primary osteogenic sarcoma. Cancer 1975;36(5):1598–602. PMID: 1059501.

Sutow W.W., Gehan E.A., Dyment P.G., Vietti T., Miale T. Multidrug adjuvant chemotherapy for osteosarcoma: Interim report of the Southwest Oncology Group studies. Cancer Treat Rep 1978;62(2): 265–70. PMID: 273477.

Cortez E.P., Holland J., Glidewell O. Adjuvant therapy of operable primary osteosarcoma-cancer and Leukemia Group B experience. Recent Results Cancer Res 1979;68:16–24. PMID: 288106.

Jaﬀee N., Frei E. 3rd, Traggis D., Bishop Y. Adjuvant methotrexate and citrovorum factor treatment of osteosarcoma. N Engl J Med 1974;291(19):994–7. PMID: 4606174.

doi: 10.1056/NEJM197411072911902.

Rosen G., Marcove R.C., Huvos A.G., Caparros B.I., Lane J.M., Nirenberg A., Cacavio A., Groshen S. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983;106 Suppl:55–67. PMID: 6604058.

Eilber F., Giuliano A., Eckardt J., Patterson K., Moseley S., Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5(1):21–6. PMID: 3543236.

doi: 10.1200/JCO.1987.5.1.21.

Link M.P., Goorin A.M., Miser A.W., Green A.A., Pratt C.B., Belasco J.B., Pritchard J., Malpas J.S., Baker A.R., Kirkpatrick J.A., Ayala A., Shuster J.J., Abelson H.T., Simone J.V., Vietti T. The eﬀect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314(25):1600–6. PMID: 3520317. doi: 10.1056/NEJM198606193142502.

Link M.P., Goorin A.M., Horowitz M., Meyer W.H., Belasco J., Baker A., Ayala A., Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991;(270):8–14. PMID: 1884563.

Bernthal N.M., Federman N., Eilber F.R., Nelson S.D., Eckardt J.J., Eilber F.C., Tap W.D. Long-term results (> 25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer 2012;118(23):5888–93. doi: 10.1002/cncr.27651.

Goorin A.M., Schwartzentruber D.J., Devidas M., Gebhardt M.C., Ayala A.G., Harris M.B., Helman L.J., Grier H.E., Link M.P.; Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003;21(8):1574–80. PMID: 12697883. doi: 10.1200/JCO.2003.08.165.

Bacci G., Mercuri M., Longhi A., Ferrari S., Bertoni F., Versari M., Picci P. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005;41(14):2079–85. PMID: 16115755. doi: 10.1016/j.ejca.2005.03.036.

Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., Kotz R., Salzer-Kuntschik M., Werner M., Winkelmann W., Zoubek A., Jürgens H., Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20(3):776–90. PMID: 11821461. doi: 10.1200/JCO.2002.20.3.776.

Whelan J.S., Bielack S.S., Marina N., Smeland S., Jovic G., Hook J.M., Krailo M., Anninga J., Butterfass-Bahloul T., Böhling T., Calaminus G., Capra M., Deﬀenbaugh C., Dhooge C., Eriksson M., Flanagan A.M., Gelderblom H., Goorin A., Gorlick R., Gosheger G., Grimer R.J., Hall K.S., Helmke K., Hogendoorn P.C., Jundt G., Kager L., Kuehne T., Lau C.C., Letson G.D., Meyer J., Meyers P.A., Morris C., Mottl H., Nadel H., Nagarajan R., Randall R.L., Schomberg P., Schwarz R., Teot L.A., Sydes M.R., Bernstein M.; EURAMOS collaborators. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 2015;26(2):407–14. doi: 10.1093/annonc/mdu526.

Kung F.H., Pratt C.B., Vega R.A., Jaﬀe N., Strother D., Schwenn M., Nitschke R., Homans A.C., Holbrook C.T., Golembe B. Ifosfamide/ etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group phase II study. Cancer 1993;71(5):1898–903. PMID: 8448755.

Gasparini M. High-dose ifosfamide alone and in combination for solid malignancies in childhood. Cancer Chemother Pharmacol 1986;18 Suppl 2:S18. PMID: 3102090.

Goorin A.M., Harris M.B., Bernstein M., Ferguson W., Devidas M., Siegal G.P., Gebhardt M.C., Schwartz C.L., Link M., Grier H.E. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002;20(2):426–33. PMID: 11786570.

doi: 10.1200/JCO.2002.20.2.426.

Ferrari S., Mercuri M., Picci P., Bertoni F., Brach del Prever A., Tienghi A., Mancini A., Longhi A., Rimondini S., Donati D., Manfrini M., Ruggieri P., Biagini R., Bacci G. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 1999;85(6):458–64. PMID: 10774566.

Marina N.M., Smeland S., Bielack S.S., Bernstein M., Jovic G., Krailo M.D., Hook J.M., Arndt C., van den Berg H., Brennan B., Brichard B., Brown K.L.B., Butterfass-Bahloul T., Calaminus G., Daldrup-Link H.E., Eriksson M., Gebhardt M.C., Gelderblom H., Gerss J., Goldsby R., Goorin A., Gorlick R., Grier H.E., Hale J.P., Hall K.S., Hardes J., Hawkins D.S., Helmke K., Hogendoorn P.C.W., Isakoﬀ M.S., Janeway K.A., Jürgens H., Kager L., Kühne T., Lau C.C., Leavey P.J., Lessnick S.L., Mascarenhas L., Meyers P.A., Mottl H., Nathrath M., Papai Z., Randall R.L., Reichardt P., Renard M., Safwat A.A., Schwartz C.L., Stevens M.C.G., Strauss S.J., Teot L., Werner M., Sydes M.R., Whelan J.S. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 2016;17(10):1396–408. doi: 10.1016/S1470-2045(16)30214-5.

Ferrari S., Ruggieri P., Cefalo G., Tamburini A., Capanna R., Fagioli F., Comandone A., Bertulli R., Bisogno G., Palmerini E., Alberghini M., Paraﬁoriti A., Linari A., Picci P., Bacci G. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol 2012;30(17):2112–8. doi: 10.1200/JCO.2011.38.4420.

Meyers P.A., Schwartz C.L., Krailo M.D., Healey J.H., Bernstein M.L., Betcher D., Ferguson W.S., Gebhardt M.C., Goorin A.M., Harris M., Kleinerman E., Link M.P., Nadel H., Nieder M., Siegal G.P., Weiner M.A., Wells R.J., Womer R.B., Grier H.E.; Childrenʼs Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Childrenʼs Oncology Group. J Clin Oncol 2008;26(4):633–8.

doi: 10.1200/JCO.2008.14.0095.

Lewis I.J., Nooij M.A., Whelan J., Sydes M.R., Grimer R., Hogendoorn P.C., Memon M.A., Weeden S., Uscinska B.M., van Glabbeke M., Kirkpatrick A., Hauben E.I., Craft A.W., Taminiau A.H.; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensiﬁed chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99(2):112–28. PMID: 17227995. doi: 10.1093/jnci/djk015.

Bielack S.S., Smeland S., Whelan J.S., Marina N., Jovic G., Hook J.M., Krailo M.D., Gebhardt M., Pápai Z., Meyer J., Nadel H., Randall R.L., Deﬀenbaugh C., Nagarajan R., Brennan B., Letson G.D., Teot L.A., Goorin A., Baumhoer D., Kager L., Werner M., Lau C.C., Sundby Hall K., Gelderblom H., Meyers P., Gorlick R., Windhager R., Helmke K., Eriksson M., Hoogerbrugge P.M., Schomberg P., Tunn P.U., Kühne T., Jürgens H., van den Berg H., Böhling T., Picton S., Renard M., Reichardt P., Gerss J., Butterfass-Bahloul T., Morris C., Hogendoorn P.C., Seddon B., Calaminus G., Michelagnoli M., Dhooge C., Sydes M.R., Bernstein M.; EURAMOS-1 investigators. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol 2015;33(20):2279–87.

doi: 10.1200/JCO.2014.60.0734.

Ward W.G., Mikaelian K., Dorey F., Mirra J.M., Sassoon A., Holmes E.C., Eilber F.R., Eckardt J.J. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994;12(9):1849–58. PMID: 8083708. doi: 10.1200/JCO.1994.12.9.1849.

Berend K.R., Pietrobon R., Moore J.O., Dibernardo L., Harellson J.M., Scully S.P. Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. J Surg Oncol 2001;78(3):162–70.

Taylor W.F., Ivins J.C., Pritchard D.J., Dahlin D.C., Gilchrist G.S., Edmonson J.H. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 1985;60(2):91–104. PMID: 3856091.

The authors declare that there are no conflicts of interest present.